Flow Neuroscience
FDA-approved at-home brain stimulation treatment for depression
- Headquarters
- Malmö
- Employees
- 11–50
- Founded
- 2016
- Business Model
- B2C
- Website
- flowneuroscience.com
- Total Funding
- $23.8M
- Last Round
- $13.0M Venture RoundOct 2025
About
Flow Neuroscience develops the world's first FDA-approved at-home tDCS (transcranial direct current stimulation) treatment for Major Depressive Disorder. The Flow FL-100 headset is a non-invasive neuromodulation device used in combination with a behavioral therapy app, providing home-based treatment for patients with moderate to severe MDD. Backed by real-world evidence from over 40,000 users and multiple clinical trials, Flow has received medical certification across Europe and the UK, and FDA approval in the US.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account